Table 2 Univariate analysis of patients’ clinical characteristics

 Localized

59 (22%)

26 (19%)

33 (24%)

.320

 Regional

49 (18%)

21 (15%)

28 (21%)

 Distant

125 (46%)

69 (51%)

56 (41%)

 Unstageable

39 (14%)

20 (15%)

19 (14%)

 Active Cancer Treatment at The Time of Event (Stroke/TIA)

94 (35%)

60 (44%)

34 (25%)

.002

 History of Chemotherapy

161 (59%)

83 (61%)

78 (57%)

.600

 History of Hormonal Therapy

32 (12%)

13 (10%)

19 (14%)

.140

 History of Radiotherapy

108 (40%)

56 (41%)

52 (38%)

.670

 History of Cancer-Related Surgery

125/ 266 (47%)

57 (42%)

68/ 130 (52%)

.070

 Atrial Fibrillation

(New onset AF or baseline AF)

25 (9%)

19 (14%)

6 (4%)

.007

 Any

246 (90%)

131 (96%)

115 (85%)

.002

 Hypertension

158 (58%)

88 (65%)

70 (52%)

.030

 Diabetes Mellitus

111 (41%)

64 (47%)

47 (35%)

.040

Smoking

Smoker = 88 (32%)

Ex-smoker = 43 (16%)

Smoker = 45 (33%)

Ex-Smoker = 22 (16%)

Smoker = 43 (32%)

Ex-smoker = 21 (15%)

.950

Dyslipidemia

68 (25%)

46 (34%)

22 (16%)

<.001

Renal Disease

56 (21%)

40 (29%)

16 (12%)

<.001

Coronary Artery Disease

52 (19%)

34 (25%)

18 (13%)

.020

Previous Ischemic Stroke

(Before Cancer Diagnosis)

43 (16%)

39 (29%)

4 (3%)

<.001

Vascular Disease

39 (14%)

25 (18%)

14 (10%)

.080

Hypothyroidism

28 (10%)

16 (12%)

12 (9%)

.560

Congestive Heart Failure

13 (4%)

11 (8%)

2 (2%)

.020

 Male < 2

105 (39%)

40 (29%)

65 (48%)

<.001

 Female < 3

 Male >= 2

167 (61%)

96 (71%)

71 (52%)

 Female >= 3

 < 3

180 (66%)

75 (55%)

105 (77%)

< .001

 >= 3

92 (34%)

61 (45%)

31 (23%)

 Anticoagulation Therapy

39 (14%)

24 (18%)

15 (11%)

.190

 Antiplatelet Therapy

68 (25%)

39 (29%)

29 (21%)

.170

 Death (at the time of study conclusion)

148 (54%)

103 (76%)

45 (33%)

< .001